CDK9 inhibition by dinaciclib is a therapeutic vulnerability in epithelioid hemangioendothelioma.

Ajaybabu V Pobbati Ashley Burtscher Nandini Rajaram Siva Andrea Hallett Todd Romigh Kepeng Che Bin Zhao Jesse A Coker Nancy Wang Shaun R Stauffer Brian P Rubin

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

The CDK inhibitor dinaciclib exhibited anti-tumorigenic properties both in vitro and in vivo in EHE models. Dinaciclib has been rigorously tested in clinical trials and displayed an acceptable toxicity profile. Therefore, there is a potential therapeutic window for repurposing dinaciclib for the treatment of EHE.

Keyphrases

clinical trial
cell cycle
climate change
oxidative stress
cell proliferation
randomized controlled trial